Autolus Therapeutics Plc (AUTL)

[jondoeuk]

The AUTO6NG product consists of three distinct populations of GD2-targeted CAR-T cells, produced by dual transduction of T-cells with two separate retroviral vectors. The first vector directs the expression of a GD2-targeting CAR, co-expressed with a constitutively signalling IL7 cytokine receptor (product A), while the second vector is a tri-cistronic retroviral vector encoding the same CAR, co-expressed with dominant negative TGF-b receptor and truncated SHP2 (product B). This yields a mix of product A/B/A+B.

Here is some preclinical data (slides from the least deck)